Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820072 | 0.85 | PDE4A (0.47) | TSHRALDH1A1MAPK1PDE4AKDM4E | |
| SCHEMBL1021779 | 0.83 | ALOX15 (0.42) | CA2CA12CA1CA7CA9 | |
| SCHEMBL28996996 | 0.83 | ACHE (0.35) | CA2CA12CA1CA7CA9 | |
| SCHEMBL3138296 | 0.81 | AMY1A (0.37) | ALDH1A1MAPK1 | |
| SCHEMBL1021627 | 0.81 | L3MBTL1 (0.41) | TSHRALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL4030548 | 0.81 | ALDH1A1 (0.44) | ACHEALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL929959 | 0.81 | RAB9A (0.46) | ALDH1A1MAPK1PTGS1PTGS2KDM4E | |
| SCHEMBL30883901 | 0.81 | RAB9A (0.46) | ALDH1A1MAPK1PTGS1PTGS2KDM4E | |
| SCHEMBL2447390 | 0.78 | MEN1 (0.54) | CYP1A2ALDH1A1CYP3A4CYP2C9KDM4E | |
| SCHEMBL14677210 | 0.77 | ALDH1A1 (0.56) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| CN-119504742-A | Total synthesis method of tylophorine and antofine | 陕西师范大学 | 2025-02-25 | — | — | CN | claimed |
| CN-114835623-B | New method for synthesizing Almond alkaloid (+/-) membrane | 河北桑迪亚医药技术有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| CN-114835623-A | New method for synthesizing Tetragoniaceae alkaloid (+/-) Mesembrine | 河北桑迪亚医药技术有限责任公司 | 2022-08-02 | — | — | CN | claimed |
| CN-104650059-B | A kind of thiazolone oxime ether derivative and its preparation method and application | 南开大学 | 2018-06-22 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| CN-119504742-B | Total synthesis method of tylophorine and antofine | 陕西师范大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-119504742-A | Total synthesis method of tylophorine and antofine | 陕西师范大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-119504742-A | Total synthesis method of tylophorine and antofine | 陕西师范大学 | 2025-02-25 | — | — | CN | disclosed |
| EP-3805193-B1 | NOVEL BIPHENYL DERIVATIVE COMPOUND AND USE THEREOF | UNIV EWHA IND COLLABORATION (KR) | 2024-09-11 | — | — | EP | disclosed |
| US-4443447-A | Phenyl-substituted tricyclic antibacterial agents | RIKER LABORATORIES, INC. (US) | 1984-04-17 | — | — | US | disclosed |
| EP-0024943-B1 | 5,6,7-TRINOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TORAY INDUSTRIES, INC. (JP) | 1983-08-17 | — | — | EP | disclosed |
| US-4387230-A | Process for preparing a dihydropyridine derivative | JOHN WYETH AND BROTHER LIMITED (GB) | 1983-06-07 | — | — | US | disclosed |
| US-4301164-A | FOR USE AS ANTIULCER AGENTS, HYPOTENSIVE AGENTS, ANTITHROMBOSIC AGENTS | TORAY INDUSTRIES, INC. (JP) | 1981-11-17 | — | — | US | disclosed |
| EP-0024943-A1 | 5,6,7-Trinor-4,8-inter-m-phenylene PGI2 derivatives and pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | CA2 1983/4885CA12 2274/4885CA1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.